Du är här


Bavarian Nordic A/S: Bavarian Nordic to Present New Evidence for Mechanism of Action for PROSTVAC Immunotherapy at the 2014 ASCO Annual Meeting

KVISTGAARD, Denmark, May 15, 2014
- Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today a paper
featuring the Company's lead cancer immunotherapy candidate PROSTVAC® will be
presented as a poster at the 2014 ASCO Annual Meeting in Chicago, IL from May
30 to June 3. The presented work provides new evidence elucidating the
mechanism of action of PROSTVAC immunotherapy for prostate cancer.

The abstract, "PROSTVAC, PSA-targeted Immunotherapy - New Evidence for
Mechanism of Action
" will be presented during the General Poster Session, Developmental
Therapeutics: Immunotherapy, Sunday, June 1, 2014 from 8:00AM to 11:45 AM
CDT. The abstract can be seen at the ASCO Annual Meeting

Abstract Highlights:

* Patients administered PROSTVAC immunotherapy showed evidence of significant
enhancement of PSA-specific T cell responses compared to subjects
administered placebo viral vectors.
* Increased numbers and improved quality of activated PSA-specific T cells
were observed with the PROSTVAC prime and boost regimen compared to single
vector regimens in preclinical models.
* The authors conclude that PROSTVAC immunotherapy elicits broad, highly
functional T cell immunity to PSA, which then expands to include immune
responses against endogenous tumor antigens not targeted by the
immunotherapy, via antigen spreading.

"These data provide important new evidence supporting and elucidating the
increase in overall survival of men with metastatic, castrate-resistant
prostate cancer in our previously published Phase 2 study. PROSTVAC is now
known to elicit an initial PSA targeted immune response. The key subsequent
event is a broadened and personalized immune response against other tumor
antigens through a process of epitope or antigen spreading," said James B.
Breitmeyer, President of Bavarian Nordic's Cancer Immunotherapy Division.

Bavarian Nordic will also be present at the conference with an exhibit, booth
#2004 where attendees can learn more about PROSTVAC and the PROSPECT clinical
trial - a global, randomized, double-blind, placebo-controlled Phase 3 study
of PROSTVAC in men with asymptomatic and minimally symptomatic metastatic,
castration-resistant prostate cancer.

Bavarian Nordic will also host a PROSTVAC update and investor and analyst
reception on Saturday, May 31, 2014 in Chicago, IL at 5 PM CDT. Confirmed
speakers and panelists include Philip Kantoff, M.D. (Dana-Farber Cancer
Institute), James L. Gulley, M.D., Ph.D. (NCI), Ravi A. Madan, M.D. (NCI),
Larry Fong, M.D. (UCSF), Winald Gerritsen, M.D., Ph.D. (Radboud University
Medical Centre Nijmegen) and James B. Breitmeyer, M.D., Ph.D. (Bavarian
Nordic). For registration and more information on this event,

Anders Hedegaard, President&CEO

Rolf Sass Sørensen, Vice President Investor Relations (EU). Phone +45 61 77 47
Seth Lewis, Vice President Investor Relations (US). Phone + 1 978-298-5654

About Bavarian Nordic
Bavarian Nordic is an international biotechnology company developing and
manufacturing novel cancer immunotherapies and vaccines for infectious
diseases. Lead product candidates are PROSTVAC®, an immunotherapy product
candidate for advanced prostate cancer that is the subject of an ongoing
pivotal Phase 3 clinical trial, and IMVAMUNE®, a non-replicating smallpox
vaccine candidate in Phase 3 development, which is being developed and
supplied for emergency use to the U.S. Strategic National Stockpile under a
contract with the U.S. Government. The vaccine is approved in Canada under
the trade name IMVAMUNE and in the European Union under the trade name

Bavarian Nordic's shares are listed on NASDAQ OMX Copenhagen under the symbol
BAVA (Reuters: BAVA.CO, Bloomberg: BAVA.DC). The company has a sponsored
Level 1 ADR program listed in the US (OTC) under the symbol BVNRY.

For more information, visitwww.bavarian-nordic.com.

Forward-looking statements
This announcement includes forward-looking statements that involve risks,
uncertainties and other factors, many of which are outside of our control
that could cause actual results to differ materially from the results
discussed in the forward-looking statements. Forward-looking statements
include statements concerning our plans, objectives, goals, future events,
performance and/or other information that is not historical information. We
undertake no obligation to publicly update or revise forward-looking
statements to reflect subsequent events or circumstances after the date made,
except as required by law.



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Bavarian Nordic A/S via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.